RTI International has won a $5.5 million contract from the National Cancer Institute for analysis of novel drug compounds and drug formulations.
The contract is for seven years. RTI will be tasked to ensure identity, purity and consistency of the drug compounds.
NCI is seeking to develop safer and more effective anti-cancer treatments.
"RTI’s analytical work is a vital step in the much larger drug development process," said John Hines, RTI’s principal investigator for the project. "We ensure that compounds being evaluated by NCI researchers are appropriately identified and quantified. In doing so, our scientists provide others in the drug development process with reliable materials and formulations they must have to precisely determine the anti-cancer therapeutic properties of new and novel anti-cancer compounds."
RTI has analyzed more than 100 compounds for the NCI since 1983.
